Teleflex Inc experienced a significant price increase of 9.00%, reaching a 20-day high amid recent market fluctuations.
The company announced the sale of its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion, aiming to optimize its portfolio and enhance competitiveness in critical healthcare markets. This strategic move is expected to provide Teleflex with approximately $1.8 billion in net proceeds, which will be used for share repurchases and debt reduction.
This transaction not only improves Teleflex's financial flexibility but also allows the company to focus on its core markets, potentially leading to mid-single-digit growth. Investors are optimistic about the long-term value creation resulting from this strategic restructuring.
Wall Street analysts forecast TFX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TFX is 136.20 USD with a low forecast of 122.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast TFX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TFX is 136.20 USD with a low forecast of 122.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
5 Hold
1 Sell
Hold
Current: 105.480
Low
122.00
Averages
136.20
High
155.00
Current: 105.480
Low
122.00
Averages
136.20
High
155.00
Wells Fargo
Equal Weight
downgrade
$139 -> $116
2026-01-29
New
Reason
Wells Fargo
Price Target
$139 -> $116
AI Analysis
2026-01-29
New
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Teleflex to $116 from $139 and keeps an Equal Weight rating on the shares. The firm is updating its estimates for the Q4 pre-announcement and recent commentary on Remainco. Wells sees Teleflex guiding to Remainco EPS of $7.50-$8.00 with upside from capital deployment.
Needham
Mike Matson
Hold -> Buy
upgrade
$138
2026-01-27
New
Reason
Needham
Mike Matson
Price Target
$138
2026-01-27
New
upgrade
Hold -> Buy
Reason
Needham analyst Mike Matson upgraded Teleflex to Buy from Hold with a $138 price target. The company is is selling its acute care, interventional urology, and manufacturing businesses for a $2B, the analyst tells investors in a research note. The firm expects "significant" earnings accretion from share repurchases and debt repayment by 2027 following the sales. Teleflex shares are trading at 9.1-times Needham's new 2027 earnings estimates, the firm points. It expects the stock to move higher as investors appreciate the company's 2027 earnings power and ability to sustain mid-single digit organic growth.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TFX
Unlock Now
Truist
Hold
maintain
$120 -> $135
2025-12-18
Reason
Truist
Price Target
$120 -> $135
2025-12-18
maintain
Hold
Reason
Truist raised the firm's price target on Teleflex to $135 from $120 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
RBC Capital
Shagun Singh
Sector Perform
maintain
$120 -> $135
2025-12-17
Reason
RBC Capital
Shagun Singh
Price Target
$120 -> $135
2025-12-17
maintain
Sector Perform
Reason
RBC Capital analyst Shagun Singh raised the firm's price target on Teleflex to $135 from $120 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that Teleflex is "a show me story" in 2026 as it executes on the planned separation of certain businesses.
About TFX
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
